In the fourth quarter of 2011, Sanofi generated sales of €8,508 million, up 8.8% on a reported basis. Exchange rate movements had a negative effect of 0.4 percentage points.
Selected by adpharm
-
Most Topular Stories
-
Sanofi fourth-quarter and full-year net sales
Breaking World Pharma News8 Feb 2012 | 2:00 pm -
FDA panel nixes new use for Amgen's Xgeva
FiercePharma9 Feb 2012 | 7:51 amThe FDA's expert advisors didn't buy Amgen's ($AMGN) argument for earlier use of its bone drug Xgeva in prostate cancer patients. The idea: Treat advanced prostate cancer patients with Xgeva to prevent or delay the disease's spread to the bone. The data: Patients who took Xgeva saw bone tumors crop up an average of 4.2 months later than those on placebo did. Overall survival time didn't differ. The vote: 12-1 against the new use. The key issues appear to be timing and side effects. Xgeva is already approved to delay fractures and stave off tumor growth in patients who have developed bone… -
India's Global Pharmacy Role Threatened By EU Pact
Drugs.com - Pharma News9 Feb 2012 | 6:49 amFrom Associated Press (February 9, 2012) NEW DELHI -- Efforts by India and the European Union to strengthen trade are threatening India's ability to deliver life-saving medicines to the world's poorest, analysts say as the two sides resume... -
Oncology KOL Views on Key Pharma Industry Issues Discussed in New...
Search for ""pharma industry" OR pharma OR pharmaceuticals"8 Feb 2012 | 9:30 amWhat are the key issues key opinion leaders raise regarding their relationship with industry? How is transparency being received and how is it affecting KOL work? Answers to all these critical questions and many more can be found in the new research study "Interacting with KOLs: Fulfilling Current Unmet Needs" prepared by FirstWord and recently ... (more) -
Ithos’ Content Management System to Maintain Cosmetic Regulatory...
MedWorm: Pharmaceuticals8 Feb 2012 | 9:10 pmIthos will be managing cosmetic regulatory assessments to strengthen compliance, mitigate risk, and enhance operational efficiencies(PRWeb February 08, 2012)Read the full story at http://www.prweb.com/releases/contentmanagementsoftware/ithosglobal/prweb9174006.htm (Source: PRWeb: Medical Pharmaceuticals)MedWorm Sponsor Message: Find the best January Sales in the UK.
-
Breaking World Pharma News
-
Sanofi fourth-quarter and full-year net sales
8 Feb 2012 | 2:00 pmIn the fourth quarter of 2011, Sanofi generated sales of €8,508 million, up 8.8% on a reported basis. Exchange rate movements had a negative effect of 0.4 percentage points. -
Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex
8 Feb 2012 | 2:00 pmSanofi (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced that Apotex has made payment in the amount of $442,209,362 to Sanofi and Bristol-Myers Squibb to satisfy the damages ruling of the Plavix® (clopidogrel bisulfate) patent infringement case against Apotex. -
Roche in 2011: Strong results and positive outlook
7 Feb 2012 | 2:00 pmThe Roche Group posted strong operating results in a challenging market in 2011. Core operating profit grew faster than sales, and Core Earnings per Share increased by 11% at constant exchange rates (-4% in Swiss francs). -
New technology to tackle treatment-resistant cancers
6 Feb 2012 | 2:00 pmFree-flowing cancer cells have been mapped with unprecedented accuracy in the bloodstream of patients with prostate, breast and pancreatic cancer, using a brand new approach, in an attempt to assess and control the disease as it spreads in real time through the body, and solve the problem of predicting response and resistance to therapies. -
Warfarin and aspirin are similar in heart failure treatment
5 Feb 2012 | 2:00 pmIn the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.
-
FiercePharma
-
FDA panel nixes new use for Amgen's Xgeva
9 Feb 2012 | 7:51 amThe FDA's expert advisors didn't buy Amgen's ($AMGN) argument for earlier use of its bone drug Xgeva in prostate cancer patients. The idea: Treat advanced prostate cancer patients with Xgeva to prevent or delay the disease's spread to the bone. The data: Patients who took Xgeva saw bone tumors crop up an average of 4.2 months later than those on placebo did. Overall survival time didn't differ. The vote: 12-1 against the new use. The key issues appear to be timing and side effects. Xgeva is already approved to delay fractures and stave off tumor growth in patients who have developed bone… -
FDA issues safety alert about PPIs and C. diff
8 Feb 2012 | 9:29 amThe FDA announced that proton-pump inhibitors used to treat heartburn and acid reflux can increase the risk of diarrhea associated with Clostridium difficile, and said it was working with drugmakers on label changes for their PPI products. C. diff disease can be difficult to treat and can lead to serious complications; it's been a growing problem in hospitals for the past several years. Release | Report -
Sanofi, BMS collect their $444M in Plavix damages
8 Feb 2012 | 9:19 amApotex has finally paid its Plavix dues. The generics maker has handed over $444 million to Sanofi ($SNY) and Bristol-Myers Squibb ($BMY), as repayment for its premature launch of generic Plavix back in 2006. The payment marks the end of a patent dispute that went on for almost 10 years, and follows Apotex's unsuccessful appeal to a U.S. Circuit Court in October. The saga began when Sanofi sued Apotex in 2002, alleging the generics company's proposed version of Plavix would infringe upon its patent. The French drugmaker won a preliminary injunction four years later--but only after Apotex had… -
Eisai renews focus on 'more attractive' Japan
8 Feb 2012 | 8:47 amEisai is coming to believe that there's no place like home. The Japanese drugmaker says it's planning to pull back in the U.S. and refocus on East Asia, and not just because markets such as China are growing so quickly. It's also because of renewal in Japan. CEO Haruo Naito told The Financial Times he's looking to grow sales in Japan, Korea, China, Hong Kong and Taiwan to account for more than their current 60% of Eisai's revenues. "There is enormous potential" in the region, he told the FT. And a good part of that potential lies in Japan, which "was mature and stagnating," Naito said, but… -
Don't look for Lundbeck earnings growth until 2015
8 Feb 2012 | 8:34 amYou can't accuse Lundbeck CEO Ulf Wiinberg of misdirection. In announcing the Danish drugmaker's latest results, Wiinberg flat-out stated that profits won't be rising anytime soon. "Growth in earnings will come in 2015, realistically," Wiinberg told Reuters. It's not as if Wiinberg could hide the company's challenges. Lundbeck is heavily dependent on its antidepressant Cipralex, which is sold in the U.S. by Forest Laboratories ($FRX) as Lexapro. And Lexapro falls off patent next month. The company figures it will lose about 80% of its Lexapro sales to generic competition this year,…
-
Drugs.com - Pharma News
-
India's Global Pharmacy Role Threatened By EU Pact
9 Feb 2012 | 6:49 amFrom Associated Press (February 9, 2012) NEW DELHI -- Efforts by India and the European Union to strengthen trade are threatening India's ability to deliver life-saving medicines to the world's poorest, analysts say as the two sides resume... -
Leo Pharma Sales Reps File Overtime Class Action in New York Federal Court
9 Feb 2012 | 6:25 amComplaint Filed by Sanford Wittels & Heisler, LLP Details Current and Past Federal & State Wage and Hour Violations NEW YORK, Feb. 9, 2012 /PRNewswire/ -- Just weeks after winning preliminary approval of a 99 million dollar settlement on... -
Bayer and Almirall to Co-Promote Anticoagulant Rivaroxaban in Spain
9 Feb 2012 | 5:59 amBayer and Almirall to co-promote anticoagulant Rivaroxaban in Spain •Rivaroxaban an innovative oral anticoagulant developed by Bayer, is a new option for stroke prevention in atrial fibrillation recently approved in Europe and the United... -
Ernst-&-Young-Fined
9 Feb 2012 | 5:29 amUS-Ernst-&-Young-Fined From Canadian Press Broadcast Wire (Canada) (February 8, 2012) WASHINGTON - The watchdog agency for the accounting industry said Wednesday that it has fined big firm Ernst & Young $2 million for alleged lapses in three... -
'Rx' Is Stylish, Clever Satire of Drug Companies
9 Feb 2012 | 5:29 amFrom Associated Press (February 8, 2012) NEW YORK -- A lot of people hate their jobs, but not to worry: there could soon be a pill for that. In the greedy world of pharmaceutical marketing as darkly imagined by playwright Kate Fodor, workplace...
-
Search for ""pharma industry" OR pharma OR pharmaceuticals"
-
Oncology KOL Views on Key Pharma Industry Issues Discussed in New...
8 Feb 2012 | 9:30 amWhat are the key issues key opinion leaders raise regarding their relationship with industry? How is transparency being received and how is it affecting KOL work? Answers to all these critical questions and many more can be found in the new research study "Interacting with KOLs: Fulfilling Current Unmet Needs" prepared by FirstWord and recently ... (more) -
JK CM seeks Csir help in Aroma, herbal, leather initiatives
8 Feb 2012 | 6:47 amChief Minister, Omar Abdullah Wednesday sought the support of Council of Scientific Industrial Research in the promotion of aroma, herbal and leather industry in Jammu and Kashmir. -
Roche digs in for long fight for Illumina
8 Feb 2012 | 6:13 amStock index futures edged higher on Wednesday as leaders in Greece again attempted to reach a deal on reforms in exchange for a new bailout. -
Faster, More Efficient Protein Labeling Developed By Chemists
7 Feb 2012 | 1:00 amNorth Carolina State University researchers have created specially engineered mammalian cells to provide a new "chemical handle" which will enable researchers to label proteins of interest more efficiently, without disrupting the normal function of the proteins themselves or the cells in which they are found. -
Patently-O Bits & Bytes by Lawrence Higgins
5 Feb 2012 | 7:13 pmThe US Department of Commerce recently performed an audit and evaluation of the USPTO's Hoteling program.
-
MedWorm: Pharmaceuticals
-
Ithos’ Content Management System to Maintain Cosmetic Regulatory...
8 Feb 2012 | 9:10 pmIthos will be managing cosmetic regulatory assessments to strengthen compliance, mitigate risk, and enhance operational efficiencies(PRWeb February 08, 2012)Read the full story at http://www.prweb.com/releases/contentmanagementsoftware/ithosglobal/prweb9174006.htm (Source: PRWeb: Medical Pharmaceuticals)MedWorm Sponsor Message: Find the best January Sales in the UK. -
New Lawsuit Filed on Actos: AttorneyOne.com Provides Advice and...
8 Feb 2012 | 9:10 pmAccording to court documents, in a suit filed on January 17, 2012 in Southern District Court, California, no. 3:2012cv00135, John Durel claims he suffered bladder cancer after taking Actos. Actos is a...(PRWeb February 07, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9171823.htm (Source: PRWeb: Medical Pharmaceuticals) -
Pill Mills Increasing in Georgia; Atlanta Criminal Defense Attorney...
8 Feb 2012 | 9:10 pmAtlanta criminal defense lawyer Benjamin Von Schuch discusses the greater number of pill mill operations in Georgia, in addition to the criminal implications from these businesses.(PRWeb February 06, 2012)Read the full story at http://www.prweb.com/releases/2012_Georgia/Pill_Mills/prweb9171462.htm (Source: PRWeb: Medical Pharmaceuticals) -
RxLogix, A Leader in Pharmaceutical and Drug Safety, Announces the...
8 Feb 2012 | 9:10 pmRxlogix Corporation is pleased to announce the appointment of Mr. John Loucks, Chief Sales & Marketing Officer (CMO) to the organization.(PRWeb February 07, 2012)Read the full story at http://www.prweb.com/releases/drug-safety/Patient-Safety/prweb9176962.htm (Source: PRWeb: Medical Pharmaceuticals) -
Telemedicine Provider MD 247 Partners with Healthcare Provider Optum...
8 Feb 2012 | 9:10 pmSeminole Florida based telemedicine provider MD 247 announced today that they have partnered with Optum Health Allies, a division of the United Health Network, in order to complete a full healthcare...(PRWeb February 06, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9169231.htm (Source: PRWeb: Medical Pharmaceuticals)
-
Pharmaceutical Industry | Processing & Engineering: Knowledge, News and Analysis | Pharmaceutical Manufacturing
-
Biomedical Industry Loses Momentum in California, According to 2012 Report
8 Feb 2012 | 12:00 amInnovation slows as productivity in the Biomedical industry declines -
Webcast: Facilities of the Future, Today
8 Feb 2012 | 12:00 amJoin us for a review and moderated discussion of the issues and technologies driving new pharmaceutical manufacturing facility design and construction, both in the U.S. and in growing Asian markets. Among the questions, in the U.S. are: where are the facilities being built and how will that affect industry employment trends? How are they being designed? -
On Shire, Single-Use and Simplicity
7 Feb 2012 | 12:00 amCRB’s Eric Unrau talks about what worked at Shire Lexington, and what limitations need to be oversome for single-use systems. -
PharmaView: Coming to America: European Companies Buy In and Lease
6 Feb 2012 | 12:00 am"OUS" companies are enjoying the U.S. market, and creating a few jobs along the way. -
Digital Insights: Scientists & Twitter
6 Feb 2012 | 12:00 amTwitter's impact on the scientific community and scientific literature citations in particular is growing at a rapid rate.
-
Pharma Marketing Blog
-
ePharma, the "Ron Paul" of Pharma Marketing - We Are the 1%
8 Feb 2012 | 5:13 amAt yesterday's ePharma Summit conference session on "Jumpstarting Digital Capabilities in Pharma: Learning from Other Industries," the presenter, Pete Mehr, Chief Healthcare Strategy Officer at Merkle, Inc., asked the audience "If you agree with the general thrust of this conference, how come it hasn't happened?" By "general thrust" he meant that pharma must get more involved in eMarketing and -
Bayer's CEO Accuses Patients of Being Ungrateful B*stards! We Cured Cancer, Dammit!
7 Feb 2012 | 5:00 amThat's my takeaway from this comment by Marijn Dekkers, "outspoken" head of Bayer Pharmaceuticals, in which he not only disses patients but claims to have cured cancer! "If you have cancer, you get a pharmaceutical product, and your cancer goes away. You're quick to call the doctor and [say] the staff at the hospital was great. But the pill that did it gets forgotten. We struggle with getting -
Pfizer's Contraceptive Recall: A Statistical Needle in a Haystack!
2 Feb 2012 | 7:44 amAll day yesterday, the news swirled through social media about Pfizer's voluntary nationwide recall of contraceptive tablets due to the possibility of "inexact tablet counts or out of sequence tablets." As a result of this packaging error, the daily regimen for these oral contraceptives may be incorrect and could leave women without adequate contraception, and at risk for unintended pregnancy. -
Mining FDA's AER Database: Heaven for Hypochondriacs, Hell for Pharma
1 Feb 2012 | 6:43 amA story in yesterday's WSJ Health featured AdverseEvents Inc., a start-up company that has streamlined the FDA's "often impenetrable" adverse drug event database and made it easy to search the adverse-event reports (AERs) for more than 4,500 drugs, free and online (see here). I interviewed Brian M. Overstreet, founder and president of Adverse Events, last September on my Pharma Marketing Talk -
The Coming Pharma Digital Depression Caused by Facebook
31 Jan 2012 | 4:12 amP&G Discovers It's "Free" to Advertise on Facebook! That's the gist of an article written by Jim Edwards over at Business Insider - Advertising (read the article here). Of course, advertising on Facebook is not really free, but it's pretty darn close when compared to TV. According to the article, "P&G said it would lay off 1,600 staffers, including marketers, as part of a cost-cutting exercise.
-
Drugs.com - New Drug Applications
-
FDA Grants Genentech's Pertuzumab Priority Review for Previously Untreated HER2-Positive Metastatic Breast Cancer
7 Feb 2012 | 9:02 amSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 7, 2012 - Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application for pertuzumab and... -
Salix Pharmaceuticals Announces FDA Granting of Priority Review Designation for the Crofelemer NDA for Treatment of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy
7 Feb 2012 | 4:02 amRALEIGH, N.C.--(BUSINESS WIRE)--Feb 7, 2012 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the Company's New Drug Application (NDA)... -
Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
1 Feb 2012 | 1:02 pmSAN DIEGO, and WOODCLIFF LAKE, N.J., Feb. 1, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has notified Arena that an Endocrinologic and Metabolic Drugs... -
NPS Pharmaceuticals Announces FDA Acceptance of New Drug Application for Gattex (teduglutide) for the Treatment of Adult Short Bowel Syndrome (SBS)
31 Jan 2012 | 5:01 amBEDMINSTER, N.J.--(BUSINESS WIRE)--Jan 31, 2012 - NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announced the U.S. Food and... -
Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph+ Chronic Myeloid Leukemia
30 Jan 2012 | 7:01 amNEW YORK--(BUSINESS WIRE)--Jan 27, 2012 - Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for standard review of bosutinib as a treatment option for adult patients with...
-
Drugs.com - New Drug Approvals
-
Sanofi Announces FDA Approval of Sklice Lotion for the Treatment of Head Lice
7 Feb 2012 | 12:02 pmBRIDGEWATER, N.J., Feb. 7, 2012 /PRNewswire/ -- Sanofi announced today that the U.S. Food and Drug Administration (FDA) has approved Sklice (ivermectin) lotion, 0.5% for the topical treatment of head lice, in patients 6 months of age and older.... -
Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD
7 Feb 2012 | 9:02 amPHILADELPHIA, February 7, 2012 /PRNewswire/ -- Vyvanse (lisdexamfetamine dimesylate), an approved treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 and above, is the first medication both proven to work and approved... -
FDA Approves Janumet XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy of Janumet (sitagliptin/metformin HCl) Now Available with Once-Daily Convenience
2 Feb 2012 | 11:02 amWHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Feb 2, 2012 - Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved Janumet XR (sitagliptin and metformin hydrochloride (HCl)... -
FDA Approves Jentadueto (linagliptin/metformin hydrochloride) for the Treatment of Adult Patients with Type 2 Diabetes
1 Feb 2012 | 5:02 amRIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 30, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin... -
FDA Approves Gleevec for Expanded Use in Patients with Rare Gastrointestinal Cancer
31 Jan 2012 | 3:01 pmThe U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today’s action also highlights an increase in...
-
PharmaGossip
-
Can The Man From Heinz Keep Novartis On Top? - Forbes
9 Feb 2012 | 5:18 amvia forbes.com Posted via email from Jack's posterous -
Oops! Anti-Obesity Drug Now In Clinical Trials May Cause Rapid Bone Loss
9 Feb 2012 | 5:15 amAn endocrine hormone used in clinical trials as an anti-obesity and anti-diabetes drug causes significant and rapid bone loss in mice, raising concerns about its safe use, UT Southwestern Medical Center researchers have shown. The hormone, fibroblast growth factor 21 (FGF21), promotes bone loss by enhancing the activity of a protein that stimulates fat cells but inhibits bone cells, researchers report in a study available online in Proceedings of the National Academy of Sciences. "This hormone is a very potent regulator of bone mass," said Dr. Yihong Wan, assistant professor of pharmacology… -
GSK emptying bank accounts to limit euro zone exposure - The Irish Times -
7 Feb 2012 | 6:31 pmANDREW JACK in LondonGLAXOSMITHKLINE is emptying out tens of millions of euro each day from its bank accounts in Europe’s more fragile countries to minimise the risk of exposure to a regional banking or financial crisis.GSK chief executive Sir Andrew Witty said that since early last year the UK pharmaceutical group had been conducting “a daily sweep” to remove all cash from most euro zone countries and deposit it in banks “we think are robust and secure”.He stressed that the euro zone crisis had “settled down” and that GSK’s own debts in the Mediterranean countries had fallen… -
Drug Rep Fired for "Poor Performance", Awarded $880,000
7 Feb 2012 | 6:28 pmWhat happened. "Moore" worked for B. Braun, primarily selling pain-killing prescription drugs. Hired in October 1998, she was fired in April 2007. She was very much aware that federal law prohibits both kickback payments from drug makers to customers and promoting off-label uses—those for indications or in dosages not approved by the Federal Drug Administration—for drugs. Moore's concerns about these practices went back to early 2000, when she sent a memo to her manager about off-label promotion. In November of that year, trainers instructed drug reps on how to promote off-label uses for… -
The tricks that drug companies do live after them, their patients are oft interred with their trials
7 Feb 2012 | 6:23 pmvia davidhealy.org Posted via email from Jack's posterous
-
FreelanceSwitch
-
Tackling Freelance Projects Like a Software Developer
9 Feb 2012 | 7:00 amHave you heard about the trend of standing room only meetings? Instead of having a team sit around a conference table, they’re made to stand up for short meetings instead. The trend is becoming prevalent in tech companies, and is meant to eliminate long, boring meetings where no one pays attention. Some companies have even instituted a penalty for being late to a meeting—either through sheer humiliation or a small fee. If someone is rambling on for too long, an employee may hold up a rubber rat indicating it is time to move on. Companies make exceptions to their no-sitting rules if a… -
A 10-Step Process to a Successful Freelance Career
9 Feb 2012 | 5:00 amAs many freelancers eventually realize, going into business for yourself means you actually take on two separate (very different) full time businesses. How’s that for a surprise when you originally thought that you could blissfully code away and somehow the money would start rolling in? This is actually what happens on your path to freelance success: You dream. It starts with the fantasy of going freelance. First, you dream of the time that you can shed your cubicle life and work from home in your fuzzy slippers, and think that somehow, eventually, the money will start coming in. You dive… -
How To Deal With Criticism
8 Feb 2012 | 7:00 amWorking in the creative field means you are an open target for criticism. Someone doesn’t like your photography work, they think you’re a bad writer, or your prices are unfair. And as freelancers, it can be hard not to take criticism—no matter how well meaning—personally. I read this blog post on Forbes.com on how to deal with really tough criticism, written for people who are business leaders. While I’m not necessarily the target audience for this article, I did take away some good lessons that I’d like to share for the freelance set. The first thing we need to consider is that… -
5 Ways to Spread the Freelance Love
8 Feb 2012 | 5:00 amValentine’s Day is probably not a holiday that brings your fellow freelancers to mind. You may have made a point to recognize your clients during the December holiday season, so why not make February the time to applaud your fellow independents? Spreading good karma always pays off in some manner, whether it be a new contact, lead, or networking opportunity. Here are some ways to get started. Hire someone. You might not think of yourself as a potential client to other freelancers, but face it, you can’t be good at everything. You could tap into fellow freelancers for several aspects of… -
Build a Better Tweet
7 Feb 2012 | 7:00 amA new study from Carnegie Mellon’s School of Computer Science called “Who Gives a Tweet: Evaluating Microblogging Content Value” has unveiled what we like to read, and what we don’t like to read, on Twitter. I have to say, the results aren’t all that surprising. A team of researchers from Carnegie Mellon, MIT, and Georgia Tech launched a site asking for anonymous feedback from people like you and me in exchange for rating their tweets. Users had to sign in to their website and rate 10 tweets before getting any feedback on their own tweets. Luckily for these researchers, their…
-
Fuel Your Creativity
-
10 Designs Inspired by Microsoft’s Metro UI
25 Jan 2012 | 5:09 pmAdvertise here via BSA Since Microsoft first unveiled the Metro UI on Windows Phone 7, the rollout has been gradually taking place across every Microsoft product and website. It is the cornerstone of the Windows 8 interface and one of the most notable official uses of Metro UI available now is the excellent implementation on the Xbox 360 dashboard. The new design language has been a refreshing sign that Redmond cares about fixing its messy, bloated and ageing image, and the company is following through and executing. In the process, Metro has picked up a lot of fans in the design… -
Timeless Design, Ferrari
25 Jan 2012 | 10:10 amAdvertise here via BSA To begin with what I hope will end up being a mindful, thought-provoking article on the essence of timelessness in design, I felt it only fitting to start with what gave birth to this idea. As a designer and all around technology consultant, it’s my job to stay up-to-date with current trends and product offerings, which by its very nature is contradictory to the idea of timelessness. I’ve been grappling with this concept for over two years now. A lot of you that follow me on Twitter know that I’m an absolute nut about cars. Up until about 24 months ago my passion… -
Free Web UI Wireframe Kit
24 Jan 2012 | 3:00 amAdvertise here via BSA Sometimes you don’t need to build interactive wireframes, or may not feel all that comfortable in Visio or OmniGraffle. I know there are times I just want to open up Photoshop and start laying things out. This web UI template kit is made completely with shape objects and in some cases converted into SmartObjects. So they’re totally scalable. There are no usage restrictions but if you find them helpful give us a shout. We love hearing from you! CLICK TO DOWNLOAD via -
Shape, Color, Content – The Language of Logos
9 Jan 2012 | 5:00 amAdvertise here via BSA Before you approve that new logo you’re considering, stop for a moment to consider how people perceive visual information. The content of your logo is third in the sequence of recognition, behind shape and color, because the brain takes more time to process language. Letterforms can be very powerful in creating content and meaning. The use of initials as an identifying mark has been around for centuries, since medieval kingdoms became economic enterprises. Letterforms are often abstracted to create clever symbols which act as metaphor for the core brand positioning. -
Starting a T-Shirt Line with No Money
5 Jan 2012 | 8:25 amAdvertise here via BSA I have to admit right up front that the title of this article is a bit of hyperbole. You might be quick to think that a t-shirt line that can be started without any money cannot possibly be a good one. It’s true that we could easily end this post in a few sentences by suggesting one of the many turnkey websites that sell one-off digital printing on every product imaginable. However, I am actually referring to starting a high quality screen printed t-shirt line without any money. Thanks to the internet…this is very possible. Tell Your Story One of the main…
-
I Believe in Advertising | ONLY SELECTED ADVERTISING | Advertising Blog & Community
-
McDonald’s McCafé: Rainy Day, Lots of Questions, Good Ideas, Confession, Shy Girl
9 Feb 2012 | 2:35 am“Everything good begins with a good cup of coffee.” Advertising Agency: TBWA, Berlin, Germany Chief Creative Officer: Stefan Schmidt, Kurt Georg Dieckert Creative Director: Vesna Koselj, Lucio Regner Art Director: Andrew Morgan Account Supervisor: Christoph Erdmann Designer: Andrew Morgan -
Ed Hardy Tattoo Stickers: Legs, Belly, Waist
8 Feb 2012 | 10:35 pm“Ed Hardy. Tattoos without needles.” Advertising Agency: Y&R, Beijing, China Chief Creative Officer: Nils Andersson, Marcus Rebeschini Executive Creative Director: Gunny Park Creative Director: Ronnie Wu, Donghai Liu Copywriter: Donghai Liu, Nils Andersson, Gao Han Art Director: Ronnie Wu, Roy Luo, Rex Rui, Shi Jian Photographer: Shi Zhong -
Rialto Channel: The Kings Speech
8 Feb 2012 | 4:43 pm“Independent film for independent ideas.” Advertising Agency: DDB, Auckland, New Zealand Executive Creative Director: Toby Talbot, Andy Fackrell Creative Director: Regan Grafton Art Director: Damian Galvin Copywriter: Rory Mckechnie Head of Art: Dave Brady Planner: David McIndoe Account Director: Danielle Richards Agency Producer: Andy Robilliard Photographer: Lewis Mulatero Retoucher: Gordon Moir Designer: Renee Lam Account Manager: Brad Armstrong, Victoria Meo -
Peugeot 308 Touring: Moon, Sun, Cloud
8 Feb 2012 | 4:25 pm“Let the outside world in. 308 Touring with Panoramic Glass Roof.” Advertising Agency: Arnold Furnace, Sydney, Australia Creative Directors: Paul Fenton, Tom Spicer Copywriter / Art Director: Luke Duggan Photographer: Alan McFetridge Retoucher: Cream Studios -
Audi A1: Youhuuu
8 Feb 2012 | 11:44 am“New Audi A1 Sportback. Amusement without breaks.” Advertising Agency: Verba, Milan, Italy Executive Creative Director: Michelangelo Cianciosi, Luca Cortesini Art Director: Daniel Cambò Ilustrator: Mozart
-
advertising/design goodness - advertising and design blog
-
Ed Hardy Tattoo Stickers
9 Feb 2012 | 2:04 am“Ed Hardy. Tattoos without needles.” Agency: Y&R, Beijing, China Chief Creative Officer: Nils Andersson, Marcus Rebeschini Executive Creative Director: Gunny Park Creative Director: Ronnie Wu, Donghai Liu Copywriter: Donghai Liu, Nils Andersson, Gao Han Art Director: Ronnie Wu, Roy Luo, Rex Rui, Shi Jian Photographer: Shi Zhong -
Medicus Health Insurance
8 Feb 2012 | 2:04 am“Medical assistance for travellers.” Agency: TBWA, Buenos Aires, Argentina Chief Creative Officers: Juan Cruz Bazterrica, Guillermo Castañeda Copywriter: Emilio Pastore Art Director: Cecilia Astengo Photographer: Blumencweig-Benitez Fotografia -
Beijing Sports Radio
7 Feb 2012 | 2:08 amAgency: Ogilvy & Mather, Hong Kong Executive Creative Directors: Simon Handford, Sandy Chan Creative Director: Alvin Lim Art Directors: Alvin Lim, Sonny Tjahjadi, Jason Pan, Hubert Yeung Associate CD / Copywriter: Richard Sorensen Retoucher: A Thousand Eyes -
Amnesty International
6 Feb 2012 | 2:36 am“We’re celebrating 50 years of fighting against violence, torture and executions.” Agency: TBWA, Berlin, Germany Chief Creative Officer: Kurt Georg Dieckert, Stefan Schmidt Copywriter: Bahador Pakravesh Art Director: Behnaz Pakravesh Illustrator: Dinoso.de, Dino So, Axel Mewes -
Axe Anarchy
3 Feb 2012 | 3:25 am“New Axe Anarchy for him + for her. Unleash the chaos.” Agency: BBH, London, UK Creative Director: Dominic Goldman, David Kolbusz Creatives: Daniel Schaefer, Szymon Rose
-
Ads of the World™
-
National Ballet of Canada: Lost in Motion
8 Feb 2012 | 4:26 pmOpening on a lone male figure, Ben Shirinian’s two-minute film pulls its viewer into the world of dancer Guillaume Côté as he loses himself to his movement in an undefined, mysterious space. Combining live action with subtle visual effects, Lost in Motion encapsulates the precision and technique of the dance to beautiful effect, exposing the strength and athleticism behind it. Dancer / Choreographer: Guillaume Côté Director: Ben Shirinian Producer: Leslie Aimée Gottlieb Production Company: Krystal Levy Pictures Executive Producer: David Miller Director of Photography: Jeremy Benning… -
Peugeot 308 Touring: Moon
8 Feb 2012 | 4:16 pmLet the outside world in. 308 Touring with Panoramic Glass Roof. Advertising Agency: Arnold Furnace, Sydney, Australia Creative Directors: Paul Fenton, Tom Spicer Copywriter / Art Director: Luke Duggan Photographer: Alan McFetridge Retoucher: Cream Studios Watch all the best Super Bowl 2012 Commercials -
Peugeot 308 Touring: Sun
8 Feb 2012 | 4:16 pmLet the outside world in. 308 Touring with Panoramic Glass Roof. Advertising Agency: Arnold Furnace, Sydney, Australia Creative Directors: Paul Fenton, Tom Spicer Copywriter / Art Director: Luke Duggan Photographer: Alan McFetridge Retoucher: Cream Studios Watch all the best Super Bowl 2012 Commercials -
Peugeot 308 Touring: Cloud
8 Feb 2012 | 4:15 pmLet the outside world in. 308 Touring with Panoramic Glass Roof. Advertising Agency: Arnold Furnace, Sydney, Australia Creative Directors: Paul Fenton, Tom Spicer Copywriter / Art Director: Luke Duggan Photographer: Alan McFetridge Retoucher: Cream Studios Watch all the best Super Bowl 2012 Commercials -
Hard Rock Café: Our Other Rock Stars
8 Feb 2012 | 4:06 pmAdvertising Agency: Duncan/Channon, San Francisco, CA, USA Executive Creative Director: Robert Duncan Creative Director / Copywriter: John Munyan Associate Creative Director / Art Director: John Stewart Executive Director: Christine Gomez Account Director: Molly Lewis Account Executive: Christian Lee Production Company: Recommended Media Director: Henry Hobson Founder / CEO: Stephen Dickstein Partner / Executive Producer: Phillip Detchmendy Producer: Steph Scire DP: Warren Hansen Editorial: Barbary Post, San Francisco Editor: Nick Tomnay Editorial Producer: Susannah Wijsen Watch all the best…
